Surgery Websites
Alaoui Lab »  People »  Principal Investigator »  Hassan Lemjabbar-Alaoui. Ph.D.
Hassan Lemjabbar-Alaoui, Ph.D.

Hassan Lemjabbar-Alaoui, Ph.D.

Associate Professor of Surgery
Department of Surgery

Contact Information

2340 Sutter Street N-224, Box 1724
University of California, San Francisco
San Francisco, CA 94143-1724
415-476-9303 Phone
Open Popup

University of Paris VII, B.S., Biology, 1988-1989

University of Paris VII, M.S.,  Molecular Biology and Immunology, 1989-1991

University of Paris VI, M.S., Biochemistry, 1991-1992

University of Paris VI, Post-Master University Diploma (DU), Clinical Pharmacokinetics and Therapeutics, 1992-1993

University of Paris XIII, Post-Master DE.A of Science, Medical and Biological Engineering, 1993-1994

University of Paris XII, Ph.D.,  Molecular and Cell Biology, 1994-1997

  • 1997-1998, Scientist, Naturalia Biologia. Paris, France
  • 1998-2001, Postdoctoral Researcher, Department of Anatomy, UCSF
  • Thoracic Oncology Program
  • Thoracic Oncology Laboratory
  • Member, UCSF Helen Diller Family Comprehensive Cancer Center
  • UCSF Department of Surgery
  • Biomarkers for early cancer detection
  • DNA repair mechanisms
  • Drug resistance mechanisms
  • Embryonic signaling pathways such as Wnt signaling
  • Novel targeted therapies
  • Role of the epidermal growth factor receptor (EGFR)
  • Sulf-1 and Sulf-2

Hassan Lemjabbar-Alaoui, Ph.D. is a biomedical scientist and Principal Investigator in the Thoracic Oncology Laboratory. Dr. Alaoui received his Ph.D. from the University of Paris XII.  Since receiving his Ph.D. from the University of Paris XII, he has focused his research work on deciphering the molecular mechanisms of lung cancer and other thoracic malignancies, and discovering novel targeted therapies and diagnostic biomarkers with clinical utility for the treatment of these diseases. Dr. Alaoui began these studies in 1997 as a postdoctoral fellow/Assistant Research Anatomist in Dr. Carol Basbaum's lab at UCSF, and continued them as an Assistant Professor of Anatomy at UCSF. 

Dr. Alaoui has also been the recipient of numerous awards including the prestigious National Institutes of Health/(NIH-NCI)/ U01 grant, the Doctors Cancer Foundation award, the Pfizer-CTI Research Program award, and the American Cancer Society. 

Dr. Alaoui's research is focused on elucidating diagnostic biomarkers and developing novel targeted therapies for treatment of lung cancer, mesothelioma and esophageal cancer. My lab seeks to gain a keen understanding of the molecular mechanisms underlying these diseases. Our projects include:

  1. Investigating the role of extracellular heparan sulfate degrading sulfatases (SULFs) in tumorigenesis, and finding novel ways to target them.
  2. Discovering novel blood biomarkers for early detection and stratification of thoracic malignancies.
  3. Elucidating the molecular mechanisms of multi-drug resistance in thoracic malignancies.
  4. Developing DNA repair inhibitors for thoracic malignancies, particularly small-molecule inhibitors, which hold great promise for damaging tumor cells.
  5. Adapting cAbl inhibitors, FDA-approved for the treatment of chronic myeloid leukemia (CML), for treatment of malignant mesothelioma, a devastating and currently incurable disease. 
Data provided by UCSF Profiles, powered by CTSI
  • Extracellular Sulfatases As Novel Biomarkers For Early Detection of Cancer
    Sponsor ID:
    Funding Period:
    Aug 2012
    Jun 2017
    Principal Investigator
Data provided by UCSF Profiles, powered by CTSI
  1. Lemjabbar-Alaoui H, Peto CJ, Yang YW, Jablons DM. AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020; 10(8):2649-2676. View in PubMed
  2. Lui NS, Yang YW, van Zante A, Buchanan P, Jablons DM, Lemjabbar-Alaoui H. SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer. PLoS One. 2016; 11(2):e0148911. View in PubMed
  3. Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P. Lung cancer: Biology and treatment options. Biochim Biophys Acta. 2015 Dec; 1856(2):189-210. View in PubMed
  4. Lemjabbar-Alaoui H, McKinney A, Yang YW, Tran VM, Phillips JJ. Glycosylation alterations in lung and brain cancer. Adv Cancer Res. 2015; 126:305-44. View in PubMed
  5. Singer MS, Phillips JJ, Lemjabbar-Alaoui H, Wang YQ, Wu J, Goldman R, Rosen SD. SULF2, a heparan sulfate endosulfatase, is present in the blood of healthy individuals and increases in cirrhosis. Clin Chim Acta. 2015 Feb 02; 440:72-8. View in PubMed
  6. View All Publications


Site Directory